Truist Financial
CSTL icon

Truist Financial’s Castle Biosciences CSTL Stock Holding History

Truist Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$584K Buy
23,781
+153
+0.6% +$5.01K ﹤0.01% 1992
2025
Q4 		$919K Buy
23,628
+257
+1% +$8.29K ﹤0.01% 1702
2025
Q3 		$532K Sell
23,371
-652
-3% -$13.2K ﹤0.01% 1994
2025
Q2 		$491K Buy
24,023
+1,715
+8% +$31.8K ﹤0.01% 1978
2025
Q1 		$447K Buy
22,308
+1,005
+5% +$24.9K ﹤0.01% 1932
2024
Q4 		$568K Buy
21,303
+928
+5% +$28.3K ﹤0.01% 1799
2024
Q3 		$581K Buy
20,375
+6,158
+43% +$157K ﹤0.01% 1786
2024
Q2 		$310K Buy
14,217
+2,420
+21% +$53.9K ﹤0.01% 2278
2024
Q1 		$261K Buy
11,797
+167
+1% +$3.63K ﹤0.01% 2356
2023
Q4 		$251K Sell
11,630
-1,467
-11% -$25.8K ﹤0.01% 2409
2023
Q3 		$221K Buy
13,097
+198
+2% +$3.46K ﹤0.01% 2410
2023
Q2 		$177K Buy
+12,899
New +$261K ﹤0.01% 2458
2022
Q2 		– Sell
-6,510
Closed -$292K – 2653
2022
Q1 		$292K Buy
6,510
+379
+6% +$15.7K ﹤0.01% 2337
2021
Q4 		$262K Sell
6,131
-237
-4% -$12.4K ﹤0.01% 2450
2021
Q3 		$424K Sell
6,368
-171
-3% -$12K ﹤0.01% 2104
2021
Q2 		$480K Buy
+6,539
New +$432K ﹤0.01% 2086

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Truist Financial's CSTL Position: Q1 2026 in Review

Truist Financial increased its Castle Biosciences (CSTL) stake by 0.65% in Q1 2026, buying an estimated $5.01K and bringing the position to 23,781 shares worth $584K. The position accounts for ﹤0.01% of the portfolio, ranked #1992.

Truist Financial first reported a position in CSTL in Q2 2021 and has held it in 16 quarters since. The position peaked at $919K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Truist Financial held 23,781 shares of Castle Biosciences worth $584K as of Q1 2026.
  • Truist Financial bought 153 Castle Biosciences shares in Q1 2026, an estimated $5.01K.
  • Castle Biosciences made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #1992 holding.
  • Truist Financial first reported a position in Castle Biosciences in Q2 2021 and has held it in 16 quarters since.
  • Truist Financial's Castle Biosciences position peaked at $919K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.